NO20082674L - Heterocykliske modulatorer for ATP-bindende kassett-transportere - Google Patents

Heterocykliske modulatorer for ATP-bindende kassett-transportere

Info

Publication number: NO20082674L
Authority: NO; Norway
Prior art keywords: binding cassette; atp binding; present; cassette transporters; heterocyclic modulators
Prior art date: 2005-11-08

Application number

NO20082674A

Other languages

English (en)

Norwegian (no)

Inventor

Brian Bear

Peter D J Grootenhuis

Matthew Hamilton

Sara Hadida Ruah

Jinglan Zhou

Mark Miller

Jason Mccarthy

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-11-08

Filing date

2008-06-09

Publication date

2008-08-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37766297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20082674(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-06-09 Application filed by Vertex Pharma filed Critical Vertex Pharma

2008-08-07 Publication of NO20082674L publication Critical patent/NO20082674L/no

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/12—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4712—Cystic fibrosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Ophthalmology & Optometry (AREA)
Psychology (AREA)
Emergency Medicine (AREA)
Microbiology (AREA)
General Physics & Mathematics (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)

NO20082674A 2005-11-08 2008-06-09 Heterocykliske modulatorer for ATP-bindende kassett-transportere NO20082674L (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US73450605P	2005-11-08	2005-11-08
US75408605P	2005-12-27	2005-12-27
US80245806P	2006-05-22	2006-05-22
PCT/US2006/043289 WO2007056341A1 (en)	2005-11-08	2006-11-08	Heterocyclic modulators of atp-binding cassette transporters

Publications (1)

Publication Number	Publication Date
NO20082674L true NO20082674L (no)	2008-08-07

Family

ID=37766297

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20082674A NO20082674L (no)	2005-11-08	2008-06-09	Heterocykliske modulatorer for ATP-bindende kassett-transportere

Country Status (24)

Country	Link
US (18)	US7741321B2 (el)
EP (6)	EP3696174A1 (el)
JP (4)	JP5317184B2 (el)
KR (6)	KR101561482B1 (el)
CN (2)	CN101356170B (el)
AU (1)	AU2006311650B2 (el)
CA (1)	CA2627358C (el)
CY (3)	CY1115750T1 (el)
DK (4)	DK2404919T3 (el)
ES (5)	ES2431388T3 (el)
HK (2)	HK1125366A1 (el)
HU (2)	HUE032640T2 (el)
IL (2)	IL191141A (el)
LT (2)	LT2774925T (el)
LU (1)	LU93073I2 (el)
NL (1)	NL300812I2 (el)
NO (1)	NO20082674L (el)
NZ (1)	NZ567892A (el)
PL (4)	PL2774925T3 (el)
PT (4)	PT2774925T (el)
RU (3)	RU2463303C3 (el)
SI (4)	SI1945632T1 (el)
WO (1)	WO2007056341A1 (el)
ZA (1)	ZA200803887B (el)

Families Citing this family (165)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
MXPA06002567A (es)	2003-09-06	2006-09-04	Vertex Pharma	Moduladores de transportadores con casete de union de atp.
CN101675928A (zh) *	2003-11-14	2010-03-24	沃泰克斯药物股份有限公司	可用作atp-结合弹夹转运蛋白调控剂的噻唑和噁唑
FR2864083B1 (fr) *	2003-12-18	2007-04-13	Galderma Res & Dev	Nouveaux derives d'acides phenyl-boroniques et leurs procedes de preparation.
MXPA06008606A (es) *	2004-01-30	2007-04-13	Vertex Pharma	Moduladores de transportadores con casete de union a atp.
US7977322B2 (en)	2004-08-20	2011-07-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
CN107501099B (zh)	2004-06-24	2021-03-19	沃泰克斯药物股份有限公司	Atp-结合弹夹转运蛋白的调控剂
NZ556732A (en)	2005-01-25	2011-11-25	Synta Pharmaceuticals Corp	Pyrazine compounds for inflammation and immune-related uses
JP5143738B2 (ja)	2005-08-11	2013-02-13	バーテックスファーマシューティカルズインコーポレイテッド	嚢胞性線維症膜コンダクタンス制御因子の調節物質
EP3696174A1 (en)	2005-11-08	2020-08-19	Vertex Pharmaceuticals Incorporated	Heterocyclic modulators of atp-binding cassette transporters
US20120232059A1 (en) *	2005-11-08	2012-09-13	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette Transporters
EP2016065B1 (en) *	2005-12-28	2012-09-19	Vertex Pharmaceuticals Incorporated	1-(benzo[d][1,3]dioxol-5-yl)-n-(phenyl)cyclopropane-carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis
US7671221B2 (en) *	2005-12-28	2010-03-02	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters
EP1993360B1 (en)	2005-12-28	2017-02-08	Vertex Pharmaceuticals Incorporated	Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
HUE027630T2 (en)	2006-04-07	2016-10-28	Vertex Pharma	Modulators of ATP-binding cassette transporters
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
US8563573B2 (en) *	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
US7754739B2 (en) *	2007-05-09	2010-07-13	Vertex Pharmaceuticals Incorporated	Modulators of CFTR
AU2008247102B2 (en)	2007-05-03	2011-11-24	Pfizer Limited	2 -pyridine carboxamide derivatives as sodium channel modulators
AU2013231028B2 (en) *	2007-05-09	2016-05-26	Vertex Pharmaceuticals Incorporated	Modulators of CFTR
CN101687842B (zh) *	2007-05-09	2013-03-06	沃泰克斯药物股份有限公司	Cftr调节剂
MX2009012678A (es) *	2007-05-25	2012-09-20	Vertex Pharma	Moduladores de canal de ion y metodos de uso.
JP5389030B2 (ja)	2007-08-24	2014-01-15	バーテックスファーマシューティカルズインコーポレイテッド	（特に）嚢胞性線維症の処置に有用なイソチアゾロピリジノン
NZ598941A (en) *	2007-11-16	2013-06-28	Vertex Pharma	Isoquinoline modulators of ATP-Binding Cassette transporters
AU2013231151B2 (en) *	2007-11-16	2015-06-25	Vertex Pharmaceuticals Incorporated	Isoquinoline modulators of ATP-Binding Cassette transporters
AU2008326381B2 (en) *	2007-11-21	2014-10-23	Decode Genetics Ehf	Biaryl PDE4 inhibitors for treating inflammation
AU2016204422B2 (en) *	2007-12-07	2017-11-16	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
US20100036130A1 (en)	2007-12-07	2010-02-11	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
AU2016200431B2 (en) *	2007-12-07	2017-08-24	Vertex Pharmaceuticals Incorporated	Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
AU2013205160B2 (en) *	2007-12-07	2016-05-19	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
NZ585794A (en) *	2007-12-07	2012-05-25	Vertex Pharma	Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
US20090176839A1 (en) *	2007-12-07	2009-07-09	Ali Keshavarz-Shokri	Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
EP2225230B1 (en) *	2007-12-07	2016-11-16	Vertex Pharmaceuticals Incorporated	Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
AU2013231109B2 (en) *	2007-12-07	2015-10-29	Vertex Pharmaceuticals Incorporated	Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
AU2013205162B2 (en) *	2008-02-28	2015-07-09	Vertex Pharmaceuticals Incorporated	Heteroaryl derivatives as CFTR modulators
NZ620944A (en) *	2008-02-28	2015-02-27	Vertex Pharma	Heteroaryl derivatives as cftr modulators
AU2015228930B2 (en) *	2008-02-28	2017-02-23	Vertex Pharmaceuticals Incorporated	Heteroaryl derivatives as CFTR modulators
AU2013270464B2 (en) *	2008-03-31	2016-05-26	Vertex Pharmaceuticals Incorporated	Pyridyl derivatives as CFTR modulators
DK2615085T3 (en) *	2008-03-31	2015-10-05	Vertex Pharma	Pyridyl derivatives as CFTR modulators
CN102123729B (zh)	2008-06-26	2015-04-29	奥菲泽米有限公司	Hsp70作为酶促活性调节物的应用
US20110230428A1 (en) *	2008-07-22	2011-09-22	John Wityak	Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US8853424B2 (en)	2008-08-11	2014-10-07	Japan Science And Technology Agency	Protein cross-linking inhibitor
US20100256184A1 (en) *	2008-08-13	2010-10-07	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
GB0817207D0 (en)	2008-09-19	2008-10-29	Pimco 2664 Ltd	therapeutic apsac compounds and their use
AR073709A1 (es) *	2008-09-29	2010-11-24	Vertex Pharma	Unidades de dosis de acido 3-(6-(1-(2,2-difluorobenzeno (d) (1,3) dioxol-5-il) ciclopropancarboxamido)-3-metilpiridin-2-il) benzoico
KR20110074917A (ko)	2008-10-23	2011-07-04	버텍스 파마슈티칼스 인코포레이티드	낭포성 섬유증 막횡단 전도도 조정자의 조절인자
US8513242B2 (en)	2008-12-12	2013-08-20	Cystic Fibrosis Foundation Therapeutics, Inc.	Pyrimidine compounds and methods of making and using same
EP2821400B1 (en)	2009-03-20	2017-09-27	Vertex Pharmaceuticals Incorporated	Process for making modulators of cystic fibrosis transmembrane conductance regulator
JP2013508414A (ja)	2009-10-22	2013-03-07	バーテックスファーマシューティカルズインコーポレイテッド	嚢胞性線維症および他の慢性疾患の治療のための組成物
WO2011056477A2 (en) *	2009-10-26	2011-05-12	Zhe Lu	Methods for treating inflammation and oxidative stress related diseases
PE20121640A1 (es) *	2009-12-31	2012-12-17	Novartis Ag	Derivados de pirazina como inhibidores de bace
US8247436B2 (en)	2010-03-19	2012-08-21	Novartis Ag	Pyridine and pyrazine derivative for the treatment of CF
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
LT3150198T (lt)	2010-04-07	2021-12-10	Vertex Pharmaceuticals Incorporated	3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas
MX2012011655A (es) *	2010-04-07	2012-11-23	Vertex Pharma	Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo [d][1-3]dioxol-5-il]ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico.
CA2796602A1 (en) *	2010-04-22	2011-10-27	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions and administrations thereof
EP2560651A1 (en)	2010-04-22	2013-02-27	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions and administrations thereof
AU2011242452A1 (en) *	2010-04-22	2012-11-08	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions and administrations thereof
KR20190061096A (ko)	2010-04-22	2019-06-04	버텍스 파마슈티칼스 인코포레이티드	시클로알킬카르복스아미도-인돌 화합물의 제조 방법
AR081331A1 (es)	2010-04-23	2012-08-08	Cytokinetics Inc	Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
EP2560488B1 (en)	2010-04-23	2015-10-28	Cytokinetics, Inc.	Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es)	2010-04-23	2012-10-10	Cytokinetics Inc	Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US8754219B2 (en)	2010-04-27	2014-06-17	Calcimedica, Inc.	Compounds that modulate intracellular calcium
PL2563776T3 (pl) *	2010-04-27	2017-01-31	Calcimedica Inc	Związki, które modulują wewnątrzkomórkowy wapń
US10703722B2 (en)	2010-04-27	2020-07-07	Calcimedica, Inc.	Compounds that modulate intracellular calcium
US8563593B2 (en)	2010-06-08	2013-10-22	Vertex Pharmaceuticals Incorporated	Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US8334292B1 (en)	2010-06-14	2012-12-18	Cystic Fibrosis Foundation Therapeutics, Inc.	Pyrimidine compounds and methods of making and using same
CA2809830C (en)	2010-08-27	2019-09-10	Calcimedica, Inc.	Compounds comprising n-acyl-2-amino-1,3-thiazole for modulating intracellular calcium
RU2013125923A (ru)	2010-11-30	2015-01-10	Орфазиме Апс	СПОСОБЫ УВЕЛИЧЕНИЯ ВНУТРИКЛЕТОЧНОЙ АКТИВНОСТИ Hsp70
CN102133402B (zh) *	2011-03-24	2013-06-12	首都医科大学附属北京同仁医院	囊性纤维化跨膜转导调节因子抑制剂在制备治疗糖尿病药物中的应用
US20120316182A1 (en)	2011-06-10	2012-12-13	Calcimedica, Inc.	Compounds that modulate intracellular calcium
SG2014012926A (en)	2011-08-30	2014-06-27	Chdi Foundation Inc	Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PH12014500472A1 (en)	2011-08-30	2014-05-12	Chdi Foundation Inc	Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US9856240B2 (en)	2011-10-19	2018-01-02	Calcimedica, Inc.	Compounds that modulate intracellular calcium
MX357328B (es)	2011-11-08	2018-07-05	Vertex Pharma	Moduladores de trasportadores de casete enlazante de atp.
TWI640519B (zh) *	2011-11-29	2018-11-11	泰緯生命科技股份有限公司	Ｈｅｃ１活性調控因子及其調節方法
NZ727015A (en)	2012-01-25	2017-12-22	Vertex Pharma	Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
NZ629199A (en)	2012-02-27	2017-01-27	Vertex Pharma	Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US8674108B2 (en)	2012-04-20	2014-03-18	Vertex Pharmaceuticals Incorporated	Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
AR092857A1 (es)	2012-07-16	2015-05-06	Vertex Pharma	Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
MX2015001897A (es)	2012-08-17	2015-05-11	Bayer Cropscience Ag	Azaindolcarboxamidas y azaindoltiocarboxamidas como insecticidas y acaricidas.
HUE039864T2 (hu)	2012-11-02	2019-02-28	Vertex Pharma	Gyógyászati készítmények CFTR-közvetítette betegségek kezelésére
ITMI20122065A1 (it)	2012-12-03	2014-06-04	Univ Padova	Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
EP2970468B1 (en)	2013-03-13	2021-07-07	Novartis AG	Notch2 binding molecules for treating respiratory diseases
AU2014243818B2 (en)	2013-03-13	2017-04-20	Flatley Discovery Lab, Llc	Pyridazinone compounds and methods for the treatment of cystic fibrosis
US9771327B2 (en) *	2013-03-13	2017-09-26	Flatley Discovery Lab, Llc	Compounds and methods for the treatment of cystic fibrosis
WO2014186704A2 (en) *	2013-05-17	2014-11-20	N30 Pharmaceuticals, Inc.	Novel compounds for the treatment of cystic fibrosis
GB201311361D0 (en)	2013-06-26	2013-08-14	Pimco 2664 Ltd	Compounds and their therapeutic use
RU2016122882A (ru)	2013-11-12	2017-12-19	Вертекс Фармасьютикалз Инкорпорейтед	Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний
CN103664796A (zh) *	2013-12-06	2014-03-26	辽宁师范大学	5-[2-(5-羧基-嘧啶基)]-1,3-苯二羧酸的合成方法
WO2015143376A1 (en) *	2014-03-21	2015-09-24	Nivalis Therapeutics, Inc.	Novel compounds for the treatment of cystic fibrosis
JP6543268B2 (ja)	2014-04-15	2019-07-10	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	嚢胞性線維症膜コンダクタンス調節因子が媒介する疾患を処置するための医薬組成物
EP2932966A1 (en)	2014-04-16	2015-10-21	Novartis AG	Gamma secretase inhibitors for treating respiratory diseases
CN114588157A (zh)	2014-07-17	2022-06-07	Chdi基金会股份有限公司	用于治疗hiv相关病症的方法和组合物
GB201415381D0 (en)	2014-08-29	2014-10-15	Algipharma As	Inhalable powder formulations of alginate oligomers
CA2961097C (en)	2014-09-15	2023-09-26	Orphazyme Aps	Extended-release pharmaceutical formulation comprising arimoclomol
CA2963792A1 (en)	2014-10-06	2016-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2016057730A1 (en)	2014-10-07	2016-04-14	Strohmeier Mark	Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
US10308648B2 (en) *	2014-10-16	2019-06-04	Syros Pharmaceuticals, Inc.	Inhibitors of cyclin-dependent kinase 7 (CDK7)
UA122965C2 (uk)	2014-10-31	2021-01-27	Еббві С.А.Р.Л.	Заміщені хромани і спосіб застосування
US10302602B2 (en)	2014-11-18	2019-05-28	Vertex Pharmaceuticals Incorporated	Process of conducting high throughput testing high performance liquid chromatography
JP6650942B2 (ja)	2014-12-17	2020-02-19	ピムコ２６６４リミテッド	Ｎ−（４−ヒドロキシ−４−メチル−シクロへキシル）−４−フェニル−ベンゼンスルホンアミド化合物、及びｎ−（４−ヒドロキシ−４−メチル−シクロへキシル）−４−（２−ピリジル）−ベンゼンスルホンアミド化合物、ならびにこれらの治療上の使用
EP3778595B1 (en)	2015-02-27	2021-08-25	Calcimedica, Inc.	Pancreatitis treatment
GB201504878D0 (en)	2015-03-23	2015-05-06	Algipharma As	Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion
FR3035105A1 (fr) *	2015-04-16	2016-10-21	Metabrain Res	Derives utiles dans le traitement de l'atrophie musculaire
WO2017007755A1 (en)	2015-07-06	2017-01-12	Rodin Therapeutics, Inc.	Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
LT3319959T (lt)	2015-07-06	2021-12-27	Alkermes, Inc.	Histono deacetilazės hetero-halogeno inhibitoriai
DK3331525T3 (da)	2015-08-07	2020-12-14	Calcimedica Inc	Anvendelse af CRAC-kanal-inhibitorer til behandling af slagtilfælde og traumatisk hjerneskade
CN106432209A (zh) *	2015-08-11	2017-02-22	苏州晶云药物科技有限公司	Lumacaftor的新晶型及其制备方法
CA3000600A1 (en) *	2015-09-29	2017-04-06	Mylan Laboratories Limited	Novel forms of lumacaftor and processes for the preparation thereof
GB201517639D0 (en)	2015-10-06	2015-11-18	Algipharma As	Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract
HUE059324T2 (hu)	2015-11-06	2022-11-28	Incyte Corp	Heterociklusos vegyületek, mint PI3K-gamma inhibitorok
WO2017118915A1 (en) *	2016-01-04	2017-07-13	Dr. Reddy's Laboratories Limited	Amorphous and crystalline solid forms of lumacaftor or its complex and preparative processes thereof
AR107293A1 (es)	2016-01-05	2018-04-18	Incyte Corp	COMPUESTOS DE PIRIDINA Y PIRIDIMINA COMO INHIBIDORES DE PI3K-g
CN107033120B (zh) *	2016-02-03	2020-03-17	苏州旺山旺水生物医药有限公司	2-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)乙氰的制备方法
WO2017137900A1 (en)	2016-02-10	2017-08-17	Lupin Limited	Amorphous lumacaftor and its solid dispersion
AU2017220454A1 (en) *	2016-02-15	2018-08-09	Taisho Pharmaceutical Co., Ltd.	Azole-substituted pyridine compound
WO2017175161A1 (en) *	2016-04-07	2017-10-12	Dr. Reddy’S Laboratories Limited	Solid forms of lumacaftor, its salts and processes thereof
EP3442530A1 (en)	2016-04-13	2019-02-20	Orphazyme A/S	Heat shock proteins and cholesterol homeostasis
KR101683011B1 (ko)	2016-04-20	2016-12-07	에스텍전자 주식회사	플렉시블 필름히터를 적용한 온수모듈장치 및 이를 구비하는 온수매트
US10206915B2 (en)	2016-04-25	2019-02-19	Druggability Technologies Ip Holdco Limited	Complexes of Ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US10383865B2 (en)	2016-04-25	2019-08-20	Druggability Technologies Ip Holdco Limited	Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them
HUP1600269A2 (hu)	2016-04-25	2017-10-30	Druggability Tech Ip Holdco Ltd	Lumacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyászati készítményei
US10376501B2 (en)	2016-04-25	2019-08-13	Druggability Technologies Ip Holdco Limited	Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
HUP1600271A2 (hu)	2016-04-25	2017-10-30	Druggability Tech Ip Holdco Ltd	Ivacaftor és Lumacaftor sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadható készítményei
DK3448382T3 (da)	2016-04-29	2020-12-07	Orphazyme As	Arimoclomol til behandling af glucocerebrosidase-associerede lidelser
US10138248B2 (en)	2016-06-24	2018-11-27	Incyte Corporation	Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
HUE052205T2 (hu) *	2016-12-09	2021-04-28	Vertex Pharma	Cisztás fibrózis transzmembrán vezetõképesség szabályzó modulátora, gyógyszerészeti készítmények, kezelési eljárások és eljárás a modulátor elõállítására
EP3565814B1 (en)	2017-01-09	2024-07-10	Laurus Labs Limited	Process and crystalline forms of lumacaftor
EP3568135B1 (en)	2017-01-11	2021-04-07	Alkermes, Inc.	Bicyclic inhibitors of histone deacetylase
CN108658851B (zh) *	2017-03-27	2023-06-06	山东特珐曼药业有限公司	2-氯-3-甲基-6-酰基氨基吡啶及其制备方法和用途
KR20200037286A (ko)	2017-08-07	2020-04-08	로딘 테라퓨틱스, 인크.	히스톤 데아세틸라제의 비사이클릭 억제제
CA3020592A1 (en)	2017-10-17	2019-04-17	Apotex Inc.	Novel crystalline form of lumacaftor
US20190210973A1 (en)	2018-01-05	2019-07-11	The Curators Of The University Of Missouri	Compounds and methods for treatment of cystic fibrosis
US11793884B2 (en)	2018-01-29	2023-10-24	Ohio State Innovation Foundation	Cyclic peptidyl inhibitors of CAL-PDZ binding domain
CN110950807B (zh) *	2018-09-26	2023-03-03	中国科学院上海药物研究所	联芳基类化合物、其制备方法、药物组合物及其应用
WO2020214921A1 (en)	2019-04-17	2020-10-22	Vertex Pharmaceuticals Incorporated	Solid forms of modulators of cftr
US11465982B2 (en) *	2019-07-22	2022-10-11	Boehringer Ingelheim International Gmbh	Pyridazines
TWI867024B (zh)	2019-08-14	2024-12-21	美商維泰克斯製藥公司	囊腫纖維化跨膜傳導調節蛋白之調節劑
BR112022002606A2 (pt)	2019-08-14	2022-05-03	Vertex Pharma	Moduladores do regulador de condutância transmembrana da fibrose cística
CA3150162A1 (en)	2019-08-14	2021-02-18	Vertex Pharmaceuticals Incorporated	Crystalline forms of cftr modulators
CR20230120A (es)	2020-08-07	2023-09-01	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
EP3970718A1 (en)	2020-09-18	2022-03-23	Charité - Universitätsmedizin Berlin	New medical use of cystic fibrosis transmembrane conductance regulator (cftr) modulators
PE20231185A1 (es)	2020-10-07	2023-08-11	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica
US20230382924A1 (en)	2020-10-07	2023-11-30	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US20230373974A1 (en)	2020-10-07	2023-11-23	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
EP4225447A1 (en)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076628A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
EP4225762A1 (en)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US20230416275A1 (en)	2020-10-07	2023-12-28	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
PE20231108A1 (es)	2020-10-07	2023-07-19	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica
EP4225748A1 (en)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US20230374038A1 (en)	2020-10-07	2023-11-23	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
EP4247792A1 (en)	2020-11-19	2023-09-27	Zevra Denmark A/S	Processes for preparing arimoclomol citrate and intermediates thereof
EP4472983A1 (en)	2022-02-03	2024-12-11	Vertex Pharmaceuticals Incorporated	Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol
KR20240144973A (ko)	2022-02-03	2024-10-04	버텍스 파마슈티칼스 인코포레이티드	낭성 섬유증 치료 방법
WO2023154291A1 (en)	2022-02-08	2023-08-17	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
EP4504739A1 (en)	2022-04-06	2025-02-12	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
CN119731183A (zh)	2022-05-16	2025-03-28	弗特克斯药品有限公司	大环化合物作为cftr调节剂的固体形式和其制备
AU2023273614A1 (en)	2022-05-16	2024-11-07	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
WO2024056798A1 (en)	2022-09-15	2024-03-21	Idorsia Pharmaceuticals Ltd	Macrocyclic cftr modulators
WO2024056791A1 (en)	2022-09-15	2024-03-21	Idorsia Pharmaceuticals Ltd	Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators
WO2024072794A1 (en) *	2022-09-26	2024-04-04	Rectify Pharmaceuticals, Inc.	Pyridine carboxamide compounds and their use in treating medical conditions
WO2024072793A1 (en) *	2022-09-26	2024-04-04	Rectify Pharmaceuticals, Inc.	Pyridine carboxamide compounds and their use in treating medical conditions

Family Cites Families (260)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3758475A (en)	1971-07-20	1973-09-11	Sandoz Ag	Pyrido(2,3-d)pyrimidin 2 ones
EP0081756B1 (en)	1981-12-14	1985-05-15	MEDEA RESEARCH S.r.l.	New compounds with antiinflammatory and antitussive activity, process for their preparation and relative pharmaceutical compositions
IT1226048B (it) *	1981-12-14	1990-12-10	Medea Res Srl	Composti ad attivita'antiinfiammatoria, processo per la loro preparazione e composizioni farmaceutiche relative
US4501729A (en)	1982-12-13	1985-02-26	Research Corporation	Aerosolized amiloride treatment of retained pulmonary secretions
EP0278374A3 (de)	1987-02-06	1989-03-01	Pharmatest Apparatebau Gmbh	Vorrichtung zur Bestimmung der Wirkstoff-Freigabe von pharmazeutischen Produkten
US5304121A (en)	1990-12-28	1994-04-19	Boston Scientific Corporation	Drug delivery system making use of a hydrogel polymer coating
US5981714A (en)	1990-03-05	1999-11-09	Genzyme Corporation	Antibodies specific for cystic fibrosis transmembrane conductance regulator and uses therefor
JP3167762B2 (ja)	1990-11-27	2001-05-21	武田薬品工業株式会社	ピリドピリダジン誘導体およびその用途
US5612360A (en)	1992-06-03	1997-03-18	Eli Lilly And Company	Angiotensin II antagonists
CA2107196A1 (en)	1992-09-29	1994-03-30	Mitsubishi Chemical Corporation	Carboxamide derivatives
US6060024A (en)	1993-07-14	2000-05-09	Zymark Corporation	Automatic dissolution testing system
US5716981A (en)	1993-07-19	1998-02-10	Angiogenesis Technologies, Inc.	Anti-angiogenic compositions and methods of use
GB9317764D0 (en)	1993-08-26	1993-10-13	Pfizer Ltd	Therapeutic compound
CN1077886C (zh)	1993-10-21	2002-01-16	G·D·瑟尔公司	用作一氧化一氮合酶抑制剂的脒基衍生物
DE4405712A1 (de)	1994-02-23	1995-08-24	Basf Ag	Substituierte Naphthyridine und deren Verwendung
CA2146701A1 (en)	1994-04-11	1995-10-12	Takashi Fujita	Heterocyclic compounds having anti-diabetic activity, their preparation and their use
JP3953097B2 (ja)	1994-09-27	2007-08-01	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Ｎ−置換ピペリジニル二環式ベンゾエート誘導体
AU2788695A (en)	1994-10-28	1996-05-23	Neurosearch A/S	Patch clamp apparatus and technique having high throughput and low fluid volume requirements
US5656256A (en)	1994-12-14	1997-08-12	The University Of North Carolina At Chapel Hill	Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5510379A (en)	1994-12-19	1996-04-23	Warner-Lambert Company	Sulfonate ACAT inhibitors
US5585115A (en)	1995-01-09	1996-12-17	Edward H. Mendell Co., Inc.	Pharmaceutical excipient having improved compressability
US6099562A (en)	1996-06-13	2000-08-08	Schneider (Usa) Inc.	Drug coating with topcoat
EP0891334A1 (en)	1996-04-03	1999-01-20	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
ES2176776T3 (es)	1996-08-23	2002-12-01	Agouron Pharma	Ligandos del neuropeptido-y.
CA2276081A1 (en)	1996-12-30	1998-07-09	Lekhanh O. Tran	Inhibitors of farnesyl-protein transferase
CO4920215A1 (es)	1997-02-14	2000-05-29	Novartis Ag	Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
US5948814A (en)	1997-02-20	1999-09-07	The Curators Of The University Of Missouri	Genistein for the treatment of cystic fibrosis
WO1998047868A1 (en)	1997-04-18	1998-10-29	Smithkline Beecham Plc	Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists
ID24376A (id)	1997-10-02	2000-07-13	Sankyo Co	Turunan-turunan asam amidokarboksilat
WO1999041405A1 (en)	1998-02-17	1999-08-19	G.D. Searle & Co.	Process for the enzymatic resolution of lactams
AU4317899A (en)	1998-06-08	1999-12-30	Schering Corporation	Neuropeptide y5 receptor antagonists
US6426331B1 (en) *	1998-07-08	2002-07-30	Tularik Inc.	Inhibitors of STAT function
AUPP609198A0 (en)	1998-09-22	1998-10-15	Curtin University Of Technology	Use of non-peptidyl compounds for the treatment of insulin related ailments
EA003147B1 (ru)	1998-12-18	2003-02-27	Дюпон Фармасьютикалз Компани	N-уреидоалкилпиперидины в качестве модуляторов активности рецепторов хемокинов
IL144717A0 (en)	1999-02-24	2002-06-30	Hoffmann La Roche	Phenyl-and pyridinyl derivatives
ES2226622T3 (es) *	1999-02-24	2005-04-01	F. Hoffmann-La Roche Ag	Derivados de 4-fenil piridina y su empleo como antagonistas del receptor nk-1.
RU2236402C2 (ru)	1999-02-24	2004-09-20	Ф.Хоффманн-Ля Рош Аг	Производные 3-фенилпиридина и фармацевтическая композиция на их основе
US7407978B2 (en) *	1999-04-06	2008-08-05	Theracos, Inc.	Heterocyclic analogs of diphenylethylene compounds
UA71971C2 (en)	1999-06-04	2005-01-17	Agoron Pharmaceuticals Inc	Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
PL352285A1 (en)	1999-06-18	2003-08-11	Bayer Ag	Phenoxy fluoropyrimidines
UA74539C2 (en)	1999-12-08	2006-01-16	Pharmacia Corp	Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
WO2001046165A2 (en)	1999-12-16	2001-06-28	Novartis Ag	N-heteroaryl-amides and their use as parasiticides
JP2003519698A (ja)	2000-01-07	2003-06-24	トランスフォームファーマスーティカルズ，インコーポレイテッド	多様な固体形態のハイスループットでの形成、同定および分析
WO2001054690A1 (en)	2000-01-28	2001-08-02	Biogen, Inc.	Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses
WO2001056989A2 (en)	2000-02-01	2001-08-09	Cor Therapeutics, Inc.	Inhibitors of factor xa
WO2001081317A1 (en)	2000-04-26	2001-11-01	Gliatech, Inc.	Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives
AU2000249828A1 (en)	2000-05-03	2001-11-12	Taisho Pharmaceutical Co. Ltd.	Stat4 and stat6 binding dipeptide derivatives
US6499984B1 (en)	2000-05-22	2002-12-31	Warner-Lambert Company	Continuous production of pharmaceutical granulation
AU783857B2 (en)	2000-06-01	2005-12-15	Bristol-Myers Squibb Pharma Company	Lactams substituted by cyclic succinates as inhibitors of a beta protein production
TWI259180B (en) *	2000-08-08	2006-08-01	Hoffmann La Roche	4-Phenyl-pyridine derivatives
ATE326459T1 (de)	2000-09-15	2006-06-15	Vertex Pharma	Pyrazolverbindungen als protein-kinasehemmer
JP4272338B2 (ja)	2000-09-22	2009-06-03	バイエルアクチェンゲゼルシャフト	ピリジン誘導体
US20020115619A1 (en)	2000-10-04	2002-08-22	Rubenstein Ronald C.	Compositions and methods for treatment of cystic fibrosis
GB2367816A (en)	2000-10-09	2002-04-17	Bayer Ag	Urea- and thiourea-containing derivatives of beta-amino acids
EP1326854B1 (en)	2000-10-20	2004-06-23	MERCK PATENT GmbH	Chiral binaphthol derivatives
US6884782B2 (en)	2000-11-08	2005-04-26	Amgen Inc.	STAT modulators
AU3652102A (en)	2000-12-01	2002-06-11	Guilford Pharm Inc	Compounds and their uses
GB0102687D0 (en)	2001-02-02	2001-03-21	Pharmacia & Upjohn Spa	Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
US6531597B2 (en)	2001-02-13	2003-03-11	Hoffmann-La Roche Inc.	Process for preparation of 2-phenyl acetic acid derivatives
US6962674B2 (en)	2001-02-28	2005-11-08	Varian, Inc.	Dissolution test apparatus
JP2005520171A (ja) *	2001-04-10	2005-07-07	トランス　テック　ファーマ，インコーポレイテッド	ドラッグディスカバリーに関する、プローブ、システム、および方法
MXPA03009720A (es)	2001-04-23	2004-01-29	Hoffmann La Roche	USO DE ANTAGONISTAS DEL RECEPTOR DE NK-1 PARA TRATAMIENTO O PREVENCIoN DE HIPERPLASIA PROSTATICA BENIGNA.
BR0209920A (pt)	2001-05-22	2004-03-30	Neurogen Corp	Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratar ansiedade, depressão ou estresse e sìndrome do intestino irritável ou doença de crohn, de detectar receptores de crf1 em uma primeira amostra biológica, de demonstrar a presença ou ausência de receptores de crf1 em uma amostra biológica e de inibir a ligação de crf a um receptor de crf1, composição farmacêutica, e, embalagem
US20030083345A1 (en)	2001-07-10	2003-05-01	Torsten Hoffmann	Method of treatment and/or prevention of brain, spinal or nerve injury
US6627646B2 (en)	2001-07-17	2003-09-30	Sepracor Inc.	Norastemizole polymorphs
WO2003007945A1 (en)	2001-07-20	2003-01-30	Boehringer Ingelheim (Canada) Ltd.	Viral polymerase inhibitors
WO2003007888A2 (en)	2001-07-20	2003-01-30	Adipogenix, Inc.	Fat accumulation-modulating compounds
WO2003022852A2 (en)	2001-09-11	2003-03-20	Smithkline Beecham Corporation	Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
PA8557501A1 (es)	2001-11-12	2003-06-30	Pfizer Prod Inc	Benzamida, heteroarilamida y amidas inversas
JP2003155285A (ja)	2001-11-19	2003-05-27	Toray Ind Inc	環状含窒素誘導体
JP2003221386A (ja)	2001-11-26	2003-08-05	Takeda Chem Ind Ltd	二環性誘導体、その製造法およびその用途
MXPA04006048A (es)	2001-12-21	2004-09-27	Novo Nordisk As	Derivados de amida como activadores de glucocinasa.
TW200307539A (en)	2002-02-01	2003-12-16	Bristol Myers Squibb Co	Cycloalkyl inhibitors of potassium channel function
TW200304820A (en)	2002-03-25	2003-10-16	Avanir Pharmaceuticals	Use of benzimidazole analogs in the treatment of cell proliferation
TW200403058A (en)	2002-04-19	2004-03-01	Bristol Myers Squibb Co	Heterocyclo inhibitors of potassium channel function
FR2840807B1 (fr)	2002-06-12	2005-03-11		Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide
AU2003265398A1 (en)	2002-08-09	2004-02-25	Transtech Pharma, Inc.	Aryl and heteroaryl compounds and methods to modulate coagulation
GB0221443D0 (en)	2002-09-16	2002-10-23	Glaxo Group Ltd	Pyridine derivates
EP1554271A1 (en)	2002-10-15	2005-07-20	Rigel Pharmaceuticals, Inc.	Substituted indoles and their use as hcv inhibitors
EP1558576A4 (en)	2002-10-30	2008-04-16	Merck & Co Inc	PIPERIDINYLCYCLOPENTYLARYLBENZYLAMIDE MODULATORS OF CHEMOKIN RECEPTORACTIVITY
AU2003287449A1 (en)	2002-10-31	2004-05-25	Nanostream, Inc.	Parallel detection chromatography systems
SI1565258T1 (sl)	2002-11-26	2012-04-30	Univ Gent	Postopek in naprava za neprekinjeno mokro granulacijo materiala v prahu
CA2508780A1 (en)	2002-12-12	2004-07-01	Pharmacia Corporation	Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors
JP4716734B2 (ja)	2003-01-06	2011-07-06	イーライリリーアンドカンパニー	グルコキナーゼ活性化物質としての置換されたアリールシクロプロピルアセトアミド
CA2755297A1 (en)	2003-02-10	2004-08-26	Vertex Pharmaceuticals Incorporated	Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes
US7223788B2 (en)	2003-02-14	2007-05-29	Sanofi-Aventis Deutschland Gmbh	Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
EP1601657A1 (en) *	2003-03-12	2005-12-07	Vertex Pharmaceuticals Incorporated	Pyrazole modulators of atp-binding cassette transporters
BRPI0409914A (pt)	2003-04-30	2006-04-25	Inst For Pharm Discovery Inc	ácidos carboxìlicos substituìdos
WO2004111014A1 (en) *	2003-06-06	2004-12-23	Vertex Pharmaceuticals Incorporated	Pyrimidine derivatives as modulators of atp-binding cassette transporters
US7893094B2 (en) *	2003-06-27	2011-02-22	The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	Amphiphilic pyridinium compounds, method of making and use thereof
GB0315111D0 (en)	2003-06-27	2003-07-30	Cancer Rec Tech Ltd	Substituted 5-membered ring compounds and their use
JP2005053902A (ja)	2003-07-18	2005-03-03	Nippon Nohyaku Co Ltd	フェニルピリジン類、その中間体及びこれを有効成分とする除草剤
AP2006003559A0 (en)	2003-09-05	2006-04-30	Neurogen Corp Ventis Pharmaceuticals Inc	Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF 1 receptor ligands
MXPA06002567A (es)	2003-09-06	2006-09-04	Vertex Pharma	Moduladores de transportadores con casete de union de atp.
KR100528925B1 (ko) *	2003-09-09	2005-11-15	삼성에스디아이 주식회사	방열시트 및 이를 구비한 플라즈마 디스플레이 장치
US7534894B2 (en)	2003-09-25	2009-05-19	Wyeth	Biphenyloxy-acids
US20050070718A1 (en)	2003-09-30	2005-03-31	Abbott Gmbh & Co. Kg	Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
CN1886393A (zh)	2003-10-08	2006-12-27	沃泰克斯药物股份有限公司	含有环烷基或吡喃基基团的atp－结合弹夹转运蛋白的调控剂
JPWO2005037269A1 (ja)	2003-10-21	2006-12-28	住友製薬株式会社	新規ピペリジン誘導体
FR2861304B1 (fr)	2003-10-23	2008-07-18	Univ Grenoble 1	Modulateurs des canaux cftr
GB0325956D0 (en)	2003-11-06	2003-12-10	Addex Pharmaceuticals Sa	Novel compounds
CN101675928A (zh)	2003-11-14	2010-03-24	沃泰克斯药物股份有限公司	可用作atp-结合弹夹转运蛋白调控剂的噻唑和噁唑
EP1687001A2 (en)	2003-11-19	2006-08-09	Glaxo Group Limited	Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders
JP3746062B2 (ja)	2003-12-05	2006-02-15	第一製薬株式会社	固形製剤およびその製造方法
ES2238001B1 (es)	2004-01-21	2006-11-01	Vita Cientifica, S.L.	Nuevas formas polimorficas de ondansetron, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso como aantiemeticos.
US7977322B2 (en)	2004-08-20	2011-07-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
MXPA06008606A (es)	2004-01-30	2007-04-13	Vertex Pharma	Moduladores de transportadores con casete de union a atp.
WO2005074535A2 (en) *	2004-01-30	2005-08-18	Eisai Co., Ltd.	Cholinesterase inhibitors for spinal cord disorders
AU2005214225B2 (en)	2004-02-19	2010-05-20	Banyu Pharmaceutical Co., Ltd.	Novel sulfone amide derivative
ES2241496B1 (es)	2004-04-15	2006-12-01	Almirall Prodesfarma, S.A.	Nuevos derivados de piridina.
WO2005115399A2 (en)	2004-04-16	2005-12-08	Neurogen Corporation	Imidazopyrazines, imidazopyridines, ans imidazopyrimidines as crf1 receptor ligands
US7585885B2 (en)	2004-04-22	2009-09-08	Eli Lilly And Company	Pyrrolidine derivatives useful as BACE inhibitors
US7618978B2 (en)	2004-04-22	2009-11-17	Eli Lilly And Company	Amides as BACE inhibitors
CA2568499A1 (en)	2004-06-01	2005-12-15	Tm Bioscience Corporation	Method of detecting cystic fibrosis associated mutations
TWI356036B (en)	2004-06-09	2012-01-11	Smithkline Beecham Corp	Apparatus and method for pharmaceutical production
CN107501099B (zh) *	2004-06-24	2021-03-19	沃泰克斯药物股份有限公司	Atp-结合弹夹转运蛋白的调控剂
US8354427B2 (en)	2004-06-24	2013-01-15	Vertex Pharmaceutical Incorporated	Modulators of ATP-binding cassette transporters
US20140343098A1 (en)	2004-06-24	2014-11-20	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
JP2008504097A (ja)	2004-07-01	2008-02-14	ワーナー−ランバートカンパニーリミテッドライアビリティーカンパニー	ナノ粒子を含有する医薬組成物の調製
WO2006014427A1 (en)	2004-07-02	2006-02-09	Advancis Pharmaceutical Corporation	Tablet for pulsed delivery
RU2416608C2 (ru)	2004-08-06	2011-04-20	Оцука Фармасьютикал Ко., Лтд.	Ароматическое соединение
US20060069110A1 (en)	2004-09-27	2006-03-30	Andersen Denise L	Substituted heterocyclic compounds and methods of use
AU2005293336B2 (en)	2004-10-12	2009-05-28	Astrazeneca Ab	Quinazoline derivatives
JP5036126B2 (ja)	2004-10-19	2012-09-26	日医工株式会社	エバスチン経口投与用製剤
EP1814888A1 (en)	2004-11-15	2007-08-08	Pfizer Products Incorporated	Azabenzoxazoles for the treatment of cns disorders
RU2410372C2 (ru)	2004-12-15	2011-01-27	Домпе` Фа.Р.Ма С.П.А.	Производные 2-арилпропионовой кислоты и фармацевтические композиции, их включающие
JP4790260B2 (ja)	2004-12-22	2011-10-12	出光興産株式会社	アントラセン誘導体を用いた有機エレクトロルミネッセンス素子
JP2008528580A (ja)	2005-01-27	2008-07-31	アストラゼネカ・アクチエボラーグ	Ｐ２ｘ７受容体の阻害剤である新規二環式芳香族化合物
US7888374B2 (en)	2005-01-28	2011-02-15	Abbott Laboratories	Inhibitors of c-jun N-terminal kinases
WO2006082952A1 (ja)	2005-02-01	2006-08-10	Takeda Pharmaceutical Company Limited	アミド化合物
JP5385605B2 (ja)	2005-03-11	2014-01-08	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｐ結合カセットトランスポーターのモジュレーター
US7297700B2 (en) *	2005-03-24	2007-11-20	Renovis, Inc.	Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
TWI377206B (en)	2005-04-06	2012-11-21	Theravance Inc	Crystalline form of a quinolinone-carboxamide compound
EP1710246A1 (en)	2005-04-08	2006-10-11	Schering Aktiengesellschaft	Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer
AU2006236387A1 (en)	2005-04-18	2006-10-26	Neurogen Corporation	Subtituted heteroaryl CB1 antagonists
CN101198333A (zh)	2005-04-19	2008-06-11	拜尔药品公司	芳烷基酸衍生物及其用途
AU2006240247A1 (en)	2005-04-20	2006-11-02	Merck Sharp & Dohme Corp.	Angiotensin II receptor antagonists
CA2603900A1 (en)	2005-04-22	2006-11-02	Wyeth	Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
GB0510139D0 (en)	2005-05-18	2005-06-22	Addex Pharmaceuticals Sa	Novel compounds B1
US8822451B2 (en)	2005-05-24	2014-09-02	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
CN101208088A (zh)	2005-06-02	2008-06-25	拜尔农作物科学股份公司	苯基烷基取代的杂芳基衍生物
EP1919875A2 (en)	2005-06-21	2008-05-14	Astex Therapeutics Limited	Pyrazole derivatives and their use as pka and pkb modulators
US7316624B2 (en) *	2005-07-29	2008-01-08	Karsten Manufacturing Corporation	Golf club head for a hybrid golf club
JP5143738B2 (ja)	2005-08-11	2013-02-13	バーテックスファーマシューティカルズインコーポレイテッド	嚢胞性線維症膜コンダクタンス制御因子の調節物質
ES2367844T3 (es)	2005-08-11	2011-11-10	Vertex Pharmaceuticals, Inc.	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística.
ATE505472T1 (de)	2005-09-09	2011-04-15	Glaxosmithkline Llc	Pyridinderivate und ihre verwendung bei der behandlung psychotischer erkrankungen
ATE453384T1 (de)	2005-09-23	2010-01-15	Hoffmann La Roche	Neue dosierformulierung
RU2008118001A (ru)	2005-10-06	2009-11-20	Вертекс Фармасьютикалз Инкорпорейтед (Us)	Модуляторы атф-зависимых транспортеров
CA2625189A1 (en)	2005-10-19	2007-04-26	Gruenenthal Gmbh	Novel vanilloid receptor ligands and their use for producing medicaments
US20120232059A1 (en)	2005-11-08	2012-09-13	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette Transporters
WO2007054480A1 (en)	2005-11-08	2007-05-18	N.V. Organon	2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor
EP3696174A1 (en) *	2005-11-08	2020-08-19	Vertex Pharmaceuticals Incorporated	Heterocyclic modulators of atp-binding cassette transporters
EP1971606B1 (en)	2005-12-05	2013-04-24	GlaxoSmithKline LLC	2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
WO2007075901A2 (en)	2005-12-24	2007-07-05	Vertex Pharmaceuticals Incorporated	Quinolin- 4 - one derivatives as modulators of abc transporters
WO2007075946A1 (en)	2005-12-27	2007-07-05	Vertex Pharmaceuticals Incorporated	Compounds useful in cftr assays and methods therewith
EP2016065B1 (en)	2005-12-28	2012-09-19	Vertex Pharmaceuticals Incorporated	1-(benzo[d][1,3]dioxol-5-yl)-n-(phenyl)cyclopropane-carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis
EP1993360B1 (en)	2005-12-28	2017-02-08	Vertex Pharmaceuticals Incorporated	Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US7671221B2 (en) *	2005-12-28	2010-03-02	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters
US8158059B2 (en)	2005-12-30	2012-04-17	Sotax Corporation	Integrated dissolution processing and sample transfer system
US10022352B2 (en) *	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
HUE027630T2 (en)	2006-04-07	2016-10-28	Vertex Pharma	Modulators of ATP-binding cassette transporters
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
JP2009536969A (ja) *	2006-05-12	2009-10-22	バーテックスファーマシューティカルズインコーポレイテッド	Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミド組成物
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
CA2668305C (en)	2006-11-03	2017-01-03	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as cftr modulators
US7754739B2 (en) *	2007-05-09	2010-07-13	Vertex Pharmaceuticals Incorporated	Modulators of CFTR
JP5318400B2 (ja)	2006-11-20	2013-10-16	第一三共株式会社	レボフロキサシン含有錠剤
MX2009005622A (es)	2006-11-27	2009-06-12	Novartis Ag	Dihidro-imidazoles sustituidos y su uso en el tratamiento de tumores.
CN101206205B (zh)	2006-12-22	2011-08-10	中国科学院大连化学物理研究所	微流量液相色谱在线大体积进样的方法和专用装置
CN101209399B (zh)	2006-12-27	2010-07-28	中国科学院沈阳应用生态研究所	一种往复式振荡机样品安放与固定装置
CN101210906A (zh)	2006-12-29	2008-07-02	电子科技大学	高通量自动化药物筛选实验检测系统
US20080260820A1 (en)	2007-04-19	2008-10-23	Gilles Borrelly	Oral dosage formulations of protease-resistant polypeptides
EP2146705B1 (en)	2007-05-02	2014-03-05	Portola Pharmaceuticals, Inc.	Combination therapy with a compound acting as a platelet adp receptor inhibitor
CN101687842B (zh)	2007-05-09	2013-03-06	沃泰克斯药物股份有限公司	Cftr调节剂
CN101687883B (zh) *	2007-05-25	2012-05-23	沃泰克斯药物股份有限公司	囊性纤维化跨膜传导调节因子的调节剂
WO2009023509A2 (en)	2007-08-09	2009-02-19	Vertex Pharmaceuticals Incorporated	Therapeutic combinations useful in treating cftr related diseases
JP5389030B2 (ja) *	2007-08-24	2014-01-15	バーテックスファーマシューティカルズインコーポレイテッド	（特に）嚢胞性線維症の処置に有用なイソチアゾロピリジノン
DE102007042754A1 (de)	2007-09-07	2009-03-12	Bayer Healthcare Ag	Substituierte 6-Phenylnikotinsäuren und ihre Verwendung
CA2699382C (en)	2007-09-14	2016-05-10	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
NZ600865A (en)	2007-09-14	2014-01-31	Vertex Pharma	Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
FR2921657A1 (fr)	2007-09-28	2009-04-03	Sanofi Aventis Sa	Derives de nicotinamide, leur preparation et leur application en therapeutique
NZ598941A (en) *	2007-11-16	2013-06-28	Vertex Pharma	Isoquinoline modulators of ATP-Binding Cassette transporters
DE102007058718A1 (de)	2007-12-06	2009-06-10	Erweka Gmbh	Vorrichtung und Verfahren zur automatischen Freisetzung und Messung von Wirkstoffen aus einer Arzneizubereitung
US20100036130A1 (en)	2007-12-07	2010-02-11	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
US20090176839A1 (en)	2007-12-07	2009-07-09	Ali Keshavarz-Shokri	Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
NZ585794A (en)	2007-12-07	2012-05-25	Vertex Pharma	Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
EP2225230B1 (en)	2007-12-07	2016-11-16	Vertex Pharmaceuticals Incorporated	Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
ES2422741T3 (es)	2007-12-13	2013-09-13	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
NZ620944A (en)	2008-02-28	2015-02-27	Vertex Pharma	Heteroaryl derivatives as cftr modulators
WO2009111228A2 (en)	2008-02-29	2009-09-11	Waters Technologies Corporation	Chromatography-based monitoring and control of multiple process streams
DK2615085T3 (en)	2008-03-31	2015-10-05	Vertex Pharma	Pyridyl derivatives as CFTR modulators
GB0813709D0 (en)	2008-07-26	2008-09-03	Univ Dundee	Method and product
LT2328618T (lt)	2008-08-13	2018-03-26	Vertex Pharmaceuticals Incorporated	N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4- oksochinolin-3-karboksamido farmacinės kompozicijos ir jų įvedimas
US20100256184A1 (en)	2008-08-13	2010-10-07	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
AR073709A1 (es)	2008-09-29	2010-11-24	Vertex Pharma	Unidades de dosis de acido 3-(6-(1-(2,2-difluorobenzeno (d) (1,3) dioxol-5-il) ciclopropancarboxamido)-3-metilpiridin-2-il) benzoico
KR20110074917A (ko)	2008-10-23	2011-07-04	버텍스 파마슈티칼스 인코포레이티드	낭포성 섬유증 막횡단 전도도 조정자의 조절인자
WO2010048573A1 (en) *	2008-10-23	2010-04-29	Vertex Pharmaceuticals Incorporated	Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
US20110257223A1 (en)	2008-10-23	2011-10-20	Vertex Pharmaceuticals Incorporated	Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
NZ592687A (en)	2008-10-23	2013-04-26	Vertex Pharma	Modulators of cystic fibrosis transmembrane conductance regulator
WO2010062356A1 (en)	2008-10-31	2010-06-03	Biomerieux, Inc.	Methods for separation, characterization and/or identification of microorganisms using spectroscopy
UA104876C2 (uk)	2008-11-06	2014-03-25	Вертекс Фармасьютікалз Інкорпорейтед	Модулятори atф-зв'язувальних касетних транспортерів
AU2008363828B2 (en)	2008-11-06	2016-09-08	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
WO2010078103A1 (en) *	2008-12-30	2010-07-08	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
HUE038854T2 (hu)	2009-03-20	2018-12-28	Vertex Pharma	Cisztás fibrózis transzmembrán konduktancia regulátor modulátorai
EP2821400B1 (en)	2009-03-20	2017-09-27	Vertex Pharmaceuticals Incorporated	Process for making modulators of cystic fibrosis transmembrane conductance regulator
CN102438578A (zh)	2009-05-07	2012-05-02	基伊埃制药系统有限公司	药片生产模块和用于连续生产药片的方法
RU2543622C2 (ru) *	2009-09-17	2015-03-10	Вертекс Фармасьютикалз Инкорпорейтед	Способ получения азабициклических соединений
JP2013508414A (ja) *	2009-10-22	2013-03-07	バーテックスファーマシューティカルズインコーポレイテッド	嚢胞性線維症および他の慢性疾患の治療のための組成物
RU2568608C2 (ru) *	2009-10-23	2015-11-20	Вертекс Фармасьютикалз Инкорпорейтед	Твердые формы n-(4-(7-азабицикло[2.2.1]гептан-7-ил)-2-(трифторметил)фенил)-4-оксо-5-(трифторметил)-1,4-дигидрохинолин-3-карбоксамида
RU2553989C2 (ru) *	2009-10-23	2015-06-20	Вертекс Фармасьютикалз Инкорпорейтед	Способ получения модуляторов регулятора трансмембранной проводимости кистозного фиброза
WO2011116397A1 (en)	2010-03-19	2011-09-22	Vertex Pharmaceuticals Incorporated	Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CN106083832A (zh)	2010-03-25	2016-11-09	弗特克斯药品有限公司	(r)‑1(2,2‑二氟苯并[d][1,3]间二氧杂环戊烯‑5‑基)‑n‑(1‑(2,3‑二羟基丙基)‑6‑氟‑2‑(1‑羟基‑2‑甲基丙‑2‑基)‑1h‑吲哚‑5‑基)环丙烷甲酰胺的固体形式
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
LT3150198T (lt)	2010-04-07	2021-12-10	Vertex Pharmaceuticals Incorporated	3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas
MX2012011655A (es)	2010-04-07	2012-11-23	Vertex Pharma	Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo [d][1-3]dioxol-5-il]ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico.
EP2560651A1 (en)	2010-04-22	2013-02-27	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions and administrations thereof
AU2011242452A1 (en)	2010-04-22	2012-11-08	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions and administrations thereof
KR20190061096A (ko)	2010-04-22	2019-06-04	버텍스 파마슈티칼스 인코포레이티드	시클로알킬카르복스아미도-인돌 화합물의 제조 방법
CA2796602A1 (en)	2010-04-22	2011-10-27	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions and administrations thereof
NZ603386A (en)	2010-05-20	2015-02-27	Vertex Pharma	Pharmaceutical compositions and administrations thereof
TW201202250A (en) *	2010-05-20	2012-01-16	Vertex Pharma	Processes for producing modulators of cystic fibrosis transmembrane conductance regulator
US8563593B2 (en)	2010-06-08	2013-10-22	Vertex Pharmaceuticals Incorporated	Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
AU2011293658B2 (en)	2010-08-23	2015-03-05	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
NZ607494A (en)	2010-08-27	2015-04-24	Vertex Pharma	Pharmaceutical composition and administrations thereof
KR101719699B1 (ko) *	2010-10-05	2017-03-27	삼성전자주식회사	메모리 모듈 및 이의 제조 방법
CN102058889A (zh)	2010-11-05	2011-05-18	王定豪	包含抗凝血类药物的分散片及其应用
US8802700B2 (en) *	2010-12-10	2014-08-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters
CN102507770A (zh)	2011-10-25	2012-06-20	中国检验检疫科学研究院	检测化妆品中六氯酚的高效液相色谱法
AU2012332225A1 (en)	2011-11-02	2014-05-15	Vertex Pharmaceuticals Incorporated	Use of (N- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl] - 1, 4 - dihydro - 4 - oxoquinoline - 3 - ca rboxamide) for treating CFTR mediated diseases
US20140127901A1 (en)	2012-11-08	2014-05-08	Taiwan Semiconductor Manufacturing Company, Ltd.	Low-k damage free integration scheme for copper interconnects
MX357328B (es)	2011-11-08	2018-07-05	Vertex Pharma	Moduladores de trasportadores de casete enlazante de atp.
NZ727015A (en)	2012-01-25	2017-12-22	Vertex Pharma	Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US8798308B2 (en) *	2012-02-21	2014-08-05	Bose Corporation	Convective airflow using a passive radiator
NZ629199A (en)	2012-02-27	2017-01-27	Vertex Pharma	Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US8674108B2 (en) *	2012-04-20	2014-03-18	Vertex Pharmaceuticals Incorporated	Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
JP2013253790A (ja)	2012-06-05	2013-12-19	Chube Univ	ニバレノールの分析法
AU2013270681A1 (en)	2012-06-08	2014-12-18	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions for the treatment of CFTR -mediated disorders
AR092857A1 (es)	2012-07-16	2015-05-06	Vertex Pharma	Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
KR20200028050A (ko) *	2012-08-06	2020-03-13	피르메니히 인코포레이티드	단맛 향미 개질제
US20140092376A1 (en)	2012-10-01	2014-04-03	Momentive Performance Materials, Inc.	Container and method for in-line analysis of protein compositions
HUE039864T2 (hu)	2012-11-02	2019-02-28	Vertex Pharma	Gyógyászati készítmények CFTR-közvetítette betegségek kezelésére
WO2014089216A1 (en)	2012-12-04	2014-06-12	Tekmira Pharmaceuticals Corporation	In vitro release assay for liposome encapsulated vincristine
US20140221424A1 (en) *	2013-01-30	2014-08-07	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions for use in the treatment of cystic fibrosis
CN103743826B (zh)	2013-08-28	2015-12-02	合肥久诺医药科技有限公司	一种阿齐沙坦的高效液相色谱分析方法
CN103822976B (zh)	2013-10-15	2015-05-27	辽宁省食品药品检验所	一种测定化妆品中4-甲氧基水杨酸钾的方法
RU2016122882A (ru)	2013-11-12	2017-12-19	Вертекс Фармасьютикалз Инкорпорейтед	Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний
JP6543268B2 (ja)	2014-04-15	2019-07-10	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	嚢胞性線維症膜コンダクタンス調節因子が媒介する疾患を処置するための医薬組成物
CN104090038B (zh)	2014-07-07	2015-09-30	黄宏南	一种直接测定冬虫夏草产品中冬虫夏草多糖肽含量的方法
CN104122345B (zh)	2014-07-31	2015-08-12	国家烟草质量监督检验中心	烟用纸中1,1,1-三羟甲基丙烷的测定方法
CN104122346B (zh)	2014-07-31	2016-03-16	国家烟草质量监督检验中心	一种水基胶中尿素含量的测定方法
WO2016057730A1 (en)	2014-10-07	2016-04-14	Strohmeier Mark	Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
US10302602B2 (en)	2014-11-18	2019-05-28	Vertex Pharmaceuticals Incorporated	Process of conducting high throughput testing high performance liquid chromatography
WO2016086136A1 (en)	2014-11-26	2016-06-02	Catabasis Pharmaceuticals, Inc.	Fatty acid cysteamine conjugates of cftr modulators and their use in treating medical disorders
MA41031A (fr)	2014-11-26	2017-10-03	Catabasis Pharmaceuticals Inc	Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
CA2969587A1 (en)	2014-12-05	2016-06-09	Centre National De La Recherche Scientifique (Cnrs)	Compounds for treating cystic fibrosis
CA2974900A1 (en)	2015-01-26	2016-08-04	Rigel Pharmaceuticals, Inc.	Tetrazolones as carboxylic acid bioisosteres
TWI730959B (zh)	2015-05-19	2021-06-21	英商葛蘭素史克智慧財產發展有限公司	作為激酶抑制劑之雜環醯胺
CN105890945A (zh)	2016-04-01	2016-08-24	中国热带农业科学院分析测试中心	超声离心渗液进样快速测定土壤中速效钾的方法
US20180280349A1 (en)	2017-03-28	2018-10-04	Vertex Pharmaceuticals Incorporated	Methods of treating cystic fibrosis in patients with residual function mutations

2006
- 2006-11-08 EP EP20150602.9A patent/EP3696174A1/en active Pending
- 2006-11-08 KR KR1020137032983A patent/KR101561482B1/ko active Active
- 2006-11-08 ES ES10191575T patent/ES2431388T3/es active Active
- 2006-11-08 SI SI200631716T patent/SI1945632T1/sl unknown
- 2006-11-08 ES ES10192912.3T patent/ES2501594T3/es active Active
- 2006-11-08 DK DK10191575.9T patent/DK2404919T3/da active
- 2006-11-08 KR KR1020087013765A patent/KR101331768B1/ko active Active
- 2006-11-08 PL PL14163968T patent/PL2774925T3/pl unknown
- 2006-11-08 AU AU2006311650A patent/AU2006311650B2/en not_active Expired - Fee Related
- 2006-11-08 EP EP14163968.2A patent/EP2774925B1/en active Active
- 2006-11-08 EP EP10191575.9A patent/EP2404919B1/en active Active
- 2006-11-08 DK DK06837028.7T patent/DK1945632T3/da active
- 2006-11-08 EP EP06837028.7A patent/EP1945632B1/en active Active
- 2006-11-08 KR KR1020167014530A patent/KR20160067985A/ko not_active Ceased
- 2006-11-08 LT LTEP14163968.2T patent/LT2774925T/lt unknown
- 2006-11-08 PL PL10191575T patent/PL2404919T3/pl unknown
- 2006-11-08 SI SI200631695T patent/SI2404919T1/sl unknown
- 2006-11-08 PL PL10192912T patent/PL2395002T3/pl unknown
- 2006-11-08 ES ES14163968.2T patent/ES2619608T3/es active Active
- 2006-11-08 DK DK14163968.2T patent/DK2774925T3/en active
- 2006-11-08 SI SI200632154A patent/SI2774925T1/sl unknown
- 2006-11-08 ES ES16205718T patent/ES2778846T3/es active Active
- 2006-11-08 CN CN2006800505211A patent/CN101356170B/zh active Active
- 2006-11-08 CN CN201210278199.5A patent/CN102775396B/zh active Active
- 2006-11-08 ZA ZA200803887A patent/ZA200803887B/xx unknown
- 2006-11-08 US US11/594,431 patent/US7741321B2/en active Active
- 2006-11-08 DK DK10192912.3T patent/DK2395002T3/da active
- 2006-11-08 CA CA2627358A patent/CA2627358C/en active Active
- 2006-11-08 KR KR1020137007108A patent/KR20130034062A/ko not_active Ceased
- 2006-11-08 RU RU2008122929A patent/RU2463303C3/ru active Protection Beyond IP Right Term
- 2006-11-08 PT PT141639682T patent/PT2774925T/pt unknown
- 2006-11-08 KR KR1020157007929A patent/KR20150041174A/ko not_active Ceased
- 2006-11-08 PT PT68370287T patent/PT1945632E/pt unknown
- 2006-11-08 HU HUE14163968A patent/HUE032640T2/en unknown
- 2006-11-08 JP JP2008540115A patent/JP5317184B2/ja active Active
- 2006-11-08 PL PL06837028T patent/PL1945632T3/pl unknown
- 2006-11-08 WO PCT/US2006/043289 patent/WO2007056341A1/en active Application Filing
- 2006-11-08 NZ NZ567892A patent/NZ567892A/en unknown
- 2006-11-08 PT PT101929123T patent/PT2395002E/pt unknown
- 2006-11-08 EP EP10192912.3A patent/EP2395002B1/en active Active
- 2006-11-08 ES ES06837028.7T patent/ES2439736T3/es active Active
- 2006-11-08 PT PT101915759T patent/PT2404919E/pt unknown
- 2006-11-08 KR KR1020137007109A patent/KR20130042034A/ko not_active Ceased
- 2006-11-08 SI SI200631826T patent/SI2395002T1/sl unknown
- 2006-11-08 EP EP16205718.6A patent/EP3208272B1/en active Active
2007
- 2007-05-18 US US11/804,726 patent/US7659268B2/en active Active
2008
- 2008-04-29 IL IL191141A patent/IL191141A/en active IP Right Grant
- 2008-05-05 US US12/114,935 patent/US8993600B2/en active Active
- 2008-06-09 NO NO20082674A patent/NO20082674L/no not_active Application Discontinuation
2009
- 2009-04-17 HK HK09103553.4A patent/HK1125366A1/xx unknown
- 2009-12-04 US US12/630,874 patent/US7956052B2/en active Active
2010
- 2010-04-28 US US12/768,894 patent/US7973038B2/en active Active
2011
- 2011-03-23 US US13/069,889 patent/US8324207B2/en active Active
- 2011-05-16 US US13/108,077 patent/US8318733B2/en active Active
2012
- 2012-06-05 RU RU2012123372A patent/RU2608610C2/ru not_active Application Discontinuation
- 2012-08-27 US US13/595,225 patent/US8461156B2/en active Active
- 2012-09-03 JP JP2012193199A patent/JP5666525B2/ja active Active
- 2012-10-31 IL IL222784A patent/IL222784A/en active IP Right Grant
2013
- 2013-04-26 US US13/871,356 patent/US8741933B2/en active Active
- 2013-04-26 US US13/871,349 patent/US20130245010A1/en not_active Abandoned
- 2013-04-26 US US13/871,364 patent/US9216969B2/en active Active
- 2013-05-06 US US13/887,839 patent/US20130245011A1/en not_active Abandoned
- 2013-05-16 HK HK13105753.1A patent/HK1178892A1/xx unknown
2014
- 2014-04-25 JP JP2014091543A patent/JP5941095B2/ja active Active
- 2014-09-15 CY CY20141100743T patent/CY1115750T1/el unknown
2015
- 2015-05-01 JP JP2015094156A patent/JP2015134835A/ja active Pending
- 2015-10-28 US US14/925,804 patent/US20160143898A1/en not_active Abandoned
2016
- 2016-05-13 LT LTPA2016015C patent/LTC2404919I2/lt unknown
- 2016-05-17 LU LU93073C patent/LU93073I2/fr unknown
- 2016-05-17 CY CY2016012C patent/CY2016012I1/el unknown
- 2016-05-17 HU HUS1600023C patent/HUS1600023I1/hu unknown
- 2016-05-18 NL NL300812C patent/NL300812I2/nl unknown
- 2016-06-01 US US15/170,263 patent/US20180282311A9/en not_active Abandoned
- 2016-06-03 US US15/173,325 patent/US20170107206A1/en not_active Abandoned
- 2016-12-21 RU RU2016150386A patent/RU2765714C2/ru active
2017
- 2017-03-22 CY CY20171100364T patent/CY1118768T1/el unknown
2018
- 2018-11-21 US US16/197,732 patent/US10626111B2/en not_active Expired - Lifetime
2020
- 2020-02-13 US US16/789,945 patent/US11084804B2/en active Active
2021
- 2021-06-29 US US17/362,597 patent/US20220153729A1/en active Pending

Also Published As

Publication number	Publication date
KR20080066086A (ko)	2008-07-15
PT1945632E (pt)	2013-12-24
US7659268B2 (en)	2010-02-09
US20110172229A1 (en)	2011-07-14
US20170107206A1 (en)	2017-04-20
JP2015134835A (ja)	2015-07-27
IL191141A0 (en)	2008-12-29
US20130237569A1 (en)	2013-09-12
EP3208272B1 (en)	2020-01-08
CY1115750T1 (el)	2017-01-25
US8741933B2 (en)	2014-06-03
CN101356170B (zh)	2012-09-26
NZ567892A (en)	2010-12-24
US20170107205A1 (en)	2017-04-20
RU2765714C2 (ru)	2022-02-02
HUE032640T2 (en)	2017-10-30
RU2463303C2 (ru)	2012-10-10
US10626111B2 (en)	2020-04-21
CN102775396B (zh)	2014-10-08
ES2778846T3 (es)	2020-08-12
US9216969B2 (en)	2015-12-22
US20130237568A1 (en)	2013-09-12
HK1178892A1 (en)	2013-09-19
PT2395002E (pt)	2014-09-16
PT2404919E (pt)	2013-10-22
EP1945632A1 (en)	2008-07-23
SI2404919T1 (sl)	2013-12-31
KR20160067985A (ko)	2016-06-14
US8461156B2 (en)	2013-06-11
DK2774925T3 (en)	2017-02-27
JP2009514962A (ja)	2009-04-09
EP2774925B1 (en)	2016-12-28
SI1945632T1 (sl)	2014-03-31
RU2016150386A (ru)	2018-06-21
PL2774925T3 (pl)	2017-07-31
CA2627358A1 (en)	2007-05-18
AU2006311650A1 (en)	2007-05-18
JP5941095B2 (ja)	2016-06-29
ES2431388T3 (es)	2013-11-26
US8318733B2 (en)	2012-11-27
EP3208272A1 (en)	2017-08-23
US20120322798A1 (en)	2012-12-20
IL191141A (en)	2013-11-28
DK1945632T3 (da)	2013-12-16
AU2006311650B2 (en)	2012-02-23
US20100210638A1 (en)	2010-08-19
IL222784A0 (en)	2012-12-31
LU93073I2 (fr)	2016-07-18
ES2439736T3 (es)	2014-01-24
PT2774925T (pt)	2017-04-04
EP2774925A1 (en)	2014-09-10
IL222784A (en)	2016-06-30
US11084804B2 (en)	2021-08-10
EP2395002B1 (en)	2014-06-18
SI2395002T1 (sl)	2014-10-30
NL300812I2 (el)	2016-09-26
KR20130034062A (ko)	2013-04-04
US20160143898A1 (en)	2016-05-26
US20190322650A1 (en)	2019-10-24
JP2014139243A (ja)	2014-07-31
JP2012233011A (ja)	2012-11-29
US8324207B2 (en)	2012-12-04
RU2016150386A3 (el)	2020-02-26
US7956052B2 (en)	2011-06-07
US20180282311A9 (en)	2018-10-04
EP2395002A1 (en)	2011-12-14
CY2016012I2 (el)	2016-10-05
KR20130042034A (ko)	2013-04-25
PL2395002T3 (pl)	2015-04-30
US20080306062A1 (en)	2008-12-11
US20110312958A1 (en)	2011-12-22
WO2007056341A1 (en)	2007-05-18
CA2627358C (en)	2015-10-06
ES2501594T3 (es)	2014-10-02
US20080113985A1 (en)	2008-05-15
US7741321B2 (en)	2010-06-22
DK2395002T3 (da)	2014-09-08
LT2774925T (lt)	2017-04-10
EP2404919B1 (en)	2013-08-21
PL2404919T3 (pl)	2014-01-31
KR20140009566A (ko)	2014-01-22
JP5317184B2 (ja)	2013-10-16
DK2404919T3 (da)	2013-11-04
LTC2404919I2 (lt)	2017-12-27
US20100087435A1 (en)	2010-04-08
CY2016012I1 (el)	2016-10-05
KR101561482B1 (ko)	2015-10-20
ZA200803887B (en)	2009-12-30
RU2012123372A (ru)	2013-12-10
EP3696174A1 (en)	2020-08-19
RU2008122929A (ru)	2009-12-20
RU2608610C2 (ru)	2017-01-23
JP5666525B2 (ja)	2015-02-12
US8993600B2 (en)	2015-03-31
US20130245011A1 (en)	2013-09-19
PL1945632T3 (pl)	2014-03-31
RU2463303C3 (ru)	2022-03-01
ES2619608T3 (es)	2017-06-26
EP1945632B1 (en)	2013-09-18
US20220153729A1 (en)	2022-05-19
US20080019915A1 (en)	2008-01-24
KR101331768B1 (ko)	2013-11-22
US20130245010A1 (en)	2013-09-19
HUS1600023I1 (hu)	2016-06-28
CN101356170A (zh)	2009-01-28
CY1118768T1 (el)	2017-07-12
HK1125366A1 (en)	2009-08-07
SI2774925T1 (sl)	2017-04-26
US20210024505A1 (en)	2021-01-28
EP2404919A1 (en)	2012-01-11
KR20150041174A (ko)	2015-04-15
CN102775396A (zh)	2012-11-14
US7973038B2 (en)	2011-07-05

Publication	Publication Date	Title
NO20082674L (no)	2008-08-07	Heterocykliske modulatorer for ATP-bindende kassett-transportere
NO20062773L (no)	2006-08-08	Tiazoler og oksazoler nyttige som modulatorer av ATP-bindingskasettransportere
IN2014KN02423A (el)	2015-05-01
HK1138586A1 (en)	2010-08-27	Modulators of cftr cftr
HK1148006A1 (en)	2011-08-26	Isoquinoline modulators of atp-binding cassette transporters atp
ATE533749T1 (de)	2011-12-15	Modulatoren von atp-bindenden kassettentransportern
WO2010053471A8 (en)	2011-09-22	Modulators of atp-binding cassette transporters
WO2010054138A3 (en)	2010-11-11	Modulators of atp-binding cassette transporters
HK1140475A1 (en)	2010-10-15	Azaindole derivatives as cftr modulators
NO20061543L (no)	2006-06-06	Modulators of ATPBinding Cassette Transportm
WO2006099256A3 (en)	2006-12-07	Modulators of atp-binding cassette transporters
WO2009038913A3 (en)	2009-07-16	Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
MX341797B (es)	2016-09-02	Moduladores de transportadores con casete de union con atp.
ATE440825T1 (de)	2009-09-15	Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern
NZ586271A (en)	2012-08-31	Fused pyrimidinone derivatives as modulators of cystic fibrosis transmembrane conductance regulator
MX357328B (es)	2018-07-05	Moduladores de trasportadores de casete enlazante de atp.
WO2007044560A3 (en)	2007-06-14	Modulators of atp-binding cassette transporters
IL189178A0 (en)	2008-06-05	Thiazolyl derivatives and pharmaceutical compositions containing the same
WO2009108657A3 (en)	2009-12-03	Heteroaryl derivatives as cftr modulators
WO2007087066A3 (en)	2007-10-25	1-(benzo [d] [1,3] di0x0l-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis
NO20083220L (no)	2008-09-22	Heterocykliske derivater som modulatorer for ionekanaler
AU2010327993A8 (en)	2012-07-19	4-oxo-1H-quinoline-3-carboxamides as modulators of ATP-Binding cassette transporters
NO341679B1 (no)	2017-12-18	Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren
NO20061845L (no)	2006-06-26	Fenyl-piperazinderivater som modulatorer for muskarine reseptorer
EP2502911A3 (en)	2013-11-06	Modulators of ATP-binding cassette transporters

Legal Events

Date	Code	Title	Description
2011-06-27	FC2A	Withdrawal, rejection or dismissal of laid open patent application